Why Raptor Pharmaceuticals Shares Vaulted Higher

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Raptor Pharmaceuticals (NASDAQ: RPTP  ) , a biopharmaceutical company focused on treating rare, and often fatal, diseases, leapt by as much as 24% after the company received U.S. orphan drug exclusivity for Procysbi from the Food and Drug Administration.

So what: Procysbi, which is a treatment approved by the FDA to treat a metabolic lysosomal storage disorder known as nephropathic cystinosis, will now be protected from any form of competition for seven years, through April 30, 2020. The orphan drug designation is granted to those drugs designed to treat diseases that affect less than 200,000 people. According to Raptor, only an estimated 500 people in the U.S. and 2,000 people worldwide suffer from nephropathic cystinosis.

Now what: While this is clearly great news that Raptor is going to be able to sell Procysbi without any competition for a period of seven years, we also have to understand that it's just a starting point from a sales perspective. The U.S. peak sales estimates for the drug are only $60 million, meaning Raptor is going to need additional drug approvals if it has any hope of turning a profit. With Raptor at a valuation in excess of $500 million, I'm beginning to wonder if the company hasn't exceeded the maximum speculation limit for this flight higher and would certainly suggest taking some profits at these levels.

Craving more input? Start by adding Raptor Pharmaceuticals to your free and personalized Watchlist so you can keep up on the latest news with the company.

It's no secret that biotech stocks like Raptor have been soaring recently, but the best investment strategy is to pick great companies and stick with them for the long-term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" not only shares stocks that could help you build long-term wealth, but also winning strategies that every investor should know. Click here to grab your free copy today

Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2511096, ~/Articles/ArticleHandler.aspx, 9/30/2016 4:42:22 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 7 hours ago Sponsored by:
DOW 18,143.45 -195.79 -1.07%
S&P 500 2,151.13 -20.24 -0.93%
NASD 5,269.15 -49.39 -0.93%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/29/2016 4:00 PM
RPTP $8.97 Up +0.01 +0.11%
Raptor Pharmaceuti… CAPS Rating: **